ImmunityBio (IBRX) Cash from Financing Activities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash from Financing Activities data on file, last reported at $223.9 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $223.9 million, up 22903.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $625.1 million (up 131.17% YoY), and the FY2025 annual result was $400.2 million, up 42.12% from the prior year.
• Cash from Financing Activities grew to $223.9 million in Q1 2026 per IBRX's latest filing, from $54.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $237.5 million in Q3 2023 and troughed at -$982000.0 in Q1 2025.
• A 5-year average of $99.9 million and a median of $106.9 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 289513.33% in 2023, then slumped 109.6% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $109.9 million in 2022, then jumped by 82.41% to $200.5 million in 2023, then sank by 46.68% to $106.9 million in 2024, then plunged by 48.66% to $54.9 million in 2025, then soared by 307.92% to $223.9 million in 2026.
• Business Quant data shows IBRX's Cash from Financing Activities at $223.9 million in Q1 2026, $54.9 million in Q4 2025, and $173.5 million in Q3 2025.